Rational design of a protein-protein interaction inhibitor that activates Protein Tyrosine Phosphatase 1B.

Researchers rationally designed a cell-permeable peptide inhibitor that disrupts the interaction between oxidized PTP1B and 14-3-3ζ, thereby preventing PTP1B inactivation, enhancing its tumor-suppressive activity, and inhibiting the growth of EGFR-driven cancer cells.

The Gist

The Big Picture: A Broken Thermostat in Cancer Cells

Imagine your body is a giant, complex city. Inside every cell, there are messengers (proteins) running back and forth, sending instructions like "Grow!" or "Stop!"

One of the most important messengers is a protein called EGFR. When it gets a signal to grow, it turns on a "growth switch" by adding a tiny tag (phosphorylation) to itself. This is normal and necessary for healing wounds.

However, in cancer, this switch gets stuck in the "ON" position. The cells grow out of control, forming tumors.

Usually, the body has a "brake pedal" to stop this growth. This brake is a protein called PTP1B. Its job is to go in, remove the "growth tags," and turn the switch off.

The Problem: In cancer cells, the "brake pedal" (PTP1B) gets jammed. It gets oxidized (like a metal part rusting) and stops working. When the brake fails, the car (the cancer cell) speeds out of control.

The Discovery: How the Brake Gets Jammed

The scientists in this paper discovered why the brake gets jammed.

1. The Rust: When the cell gets a growth signal, it creates a tiny bit of "rust" (reactive oxygen species, or ROS). This rust hits the PTP1B brake.
2. The Shape Shift: When the rust hits PTP1B, the protein changes its shape. It's like a key that suddenly bends.
3. The Bad Neighbor: Because the key is bent, a sticky protein called 14-3-3z latches onto it. Think of 14-3-3z as a heavy, sticky handcuff that locks the brake pedal in the "OFF" position. As long as this handcuff is on, the brake cannot work, and the cancer grows.

The Solution: A "Decoy" Key

The researchers asked a clever question: If we can't fix the rust easily, can we just pull the handcuff off?

They designed a special peptide (a tiny piece of protein) that acts like a decoy.

• The Analogy: Imagine the handcuff (14-3-3z) is looking for a specific shape on the bent brake (PTP1B) to grab onto. The scientists made a fake, floating piece of that shape (the peptide).
• The Trick: When they put this decoy into the cell, the handcuff grabs onto the decoy instead of the real brake. The real brake is now free! The handcuff is distracted.
• The Result: The brake (PTP1B) is no longer stuck. It can go back to its normal shape, remove the "growth tags" from EGFR, and stop the cancer cell from growing.

How They Delivered the Medicine

There was a catch: These tiny decoy pieces are like soap bubbles; they can't easily get through the tough skin of a cell to do their job.

1. The First Attempt (The TAT Peptide): They attached a "key" (called TAT) to the decoy that acts like a universal pass, letting it walk right through any cell door. This worked in the lab, but it was too broad—it would unlock the brakes in healthy cells too, which could cause side effects.
2. The Smart Delivery (The pH-LIP): To be more precise, they used a "smart delivery truck" called pHLIP.
   • How it works: Cancer cells are like acidic swamps (they have a lower pH than healthy cells). The pHLIP truck only opens its doors and drops off its cargo when it senses this acidity.
   • The Benefit: This means the drug only activates the brake inside the cancer cells, leaving the healthy cells alone.

The Results: Stopping the Cancer

When they tested this on cancer cells in a dish:

• The "decoy" successfully pulled the handcuffs off the brake.
• The brake started working again, turning off the growth signals.
• The cancer cells stopped multiplying and forming colonies (little groups of cancer cells).
• In fact, the cancer cells started dying off.

Why This Matters

For a long time, scientists have tried to stop cancer by building "speed bumps" for the growth signals (kinase inhibitors). But this paper suggests a new strategy: fixing the brakes.

This is the first time scientists have successfully designed a drug that activates a phosphatase (the brake) by breaking a bad protein partnership. It opens the door for a whole new class of medicines that don't just slow down the bad guys, but restore the body's natural ability to stop them.

In short: They found a way to trick a sticky handcuff into letting go of a broken brake, allowing the cell to finally hit the brakes and stop the cancer from growing. And they built a smart delivery system to make sure the trick only happens in the cancer cells.

Technical Summary

1. Problem Statement

Protein Tyrosine Phosphatases (PTPs) are critical regulators of cell signaling, often acting as tumor suppressors by dephosphorylating growth factor receptors like EGFR. However, their activity is transiently inhibited by Reactive Oxygen Species (ROS), specifically hydrogen peroxide ($H_2O_2$), generated downstream of receptor tyrosine kinase (RTK) activation.

• The Mechanism: In the case of Protein Tyrosine Phosphatase 1B (PTP1B), reversible oxidation of its catalytic cysteine leads to the formation of a cyclic sulfenamide. This causes a conformational change where the phosphotyrosine (pTyr) binding loop (residues Lys41-Ser50) flips out and becomes solvent-exposed.
• The Consequence: This exposed loop is phosphorylated by AKT and subsequently binds to the 14-3-3$\zeta$ protein. This binding stabilizes PTP1B in its oxidized (inactive) state, prolonging RTK signaling.
• The Gap: While many tyrosine kinase inhibitors exist, there are no known specific pharmacological agents capable of activating PTPs to restore physiological signaling or counteract pathological hyper-phosphorylation in cancer.

2. Methodology

The authors employed a rational drug design approach targeting the protein-protein interaction (PPI) between oxidized PTP1B (PTP1B-OX) and 14-3-3$\zeta$.

• Peptide Design:
  • Synthesized peptides based on the pTyr loop sequence of PTP1B (Lys41-Ser50).
  • Created variants with and without Ser50 phosphorylation.
  • Conjugated these peptides to the TAT cell-penetrating sequence (N-terminal or C-terminal) to create TAT-Peptides (TP1–TP4).
  • Developed a second generation using pHLIP (pH(Low) Insertion Peptide) conjugated to the PPI inhibitor. pHLIP exploits the acidic tumor microenvironment (pH 6.0–6.8) to insert into cell membranes and deliver cargo specifically to cancer cells.
• Cell Models:
  • HEK293/HEK293T cells: Used for mechanistic studies on PTP1B-14-3-3$\zeta$ interaction and ROS production.
  • A431 cells: An EGFR-driven epidermoid carcinoma model used to assess therapeutic efficacy (colony formation and viability).
• Experimental Assays:
  • Pulldown/Co-IP: To assess the physical interaction between PTP1B and 14-3-3$\zeta$ in the presence of peptides.
  • Cysteinyl-labeling assays: Used to detect the oxidation state of PTP1B (biotinylation of reduced cysteines vs. oxidized forms).
  • Immune-complex PTP activity assay: Measured endogenous PTP1B catalytic activity using pNPP substrate under oxygen-free conditions.
  • Western Blotting: Analyzed phosphorylation levels of EGFR (specifically Tyr992 and Tyr1148, known PTP1B sites) and total EGFR.
  • ROS Measurement: Used DCFH-DA fluorescence to measure intracellular $H_2O_2$ levels.
  • Functional Assays: Colony formation and MTT viability assays to determine anti-cancer effects.
  • Biophysical Characterization: Circular Dichroism (CD) and Tryptophan fluorescence to confirm pHLIP membrane insertion at low pH.

3. Key Contributions

• First PTP Activator: This study reports the first successful design of a protein-protein interaction inhibitor that activates PTP1B, rather than inhibiting it.
• Mechanistic Insight: It elucidates that disrupting the PTP1B-OX/14-3-3$\zeta$ complex prevents the stabilization of the oxidized form, thereby keeping PTP1B in its active, reduced state.
• Targeted Delivery Strategy: The development of a pHLIP-conjugated peptide offers a novel strategy to deliver PPI inhibitors specifically to the acidic tumor microenvironment, minimizing off-target effects in healthy tissues.

4. Key Results

• Disruption of PPI: All TAT-conjugated pTyr loop peptides (TP1–TP4) successfully disrupted the interaction between PTP1B and the 14-3-3$\zeta$ complex in EGF-stimulated cells. Notably, peptides lacking the Ser50 phosphorylation site were also effective, suggesting the binding complex engages the loop before specific phosphorylation occurs.
• PTP1B Activation:
  • Treatment with TP4 (N-terminal TAT, containing Ser50) prevented the EGF-induced oxidation of PTP1B.
  • Cysteinyl-labeling assays confirmed that TP4-treated cells did not show the biotinylation pattern associated with oxidized PTP1B.
  • Immune-complex assays showed that TP4 treatment maintained high PTP1B catalytic activity even after EGF stimulation, whereas control cells showed a transient drop in activity.
• Downstream Signaling Effects:
  • TP4 treatment significantly reduced phosphorylation of EGFR at PTP1B-specific sites (Tyr992 and Tyr1148) but did not affect total EGFR phosphorylation or SRC-specific sites (Tyr845), confirming specificity.
  • The peptide did not alter the generation of ROS ($H_2O_2$) by the cells, indicating the effect is downstream of ROS production, specifically at the level of PTP1B stabilization.
• Anti-Cancer Efficacy:
  • In A431 cancer cells, TP4 treatment significantly inhibited colony formation and reduced cell viability, consistent with the tumor-suppressive role of active PTP1B.
• pHLIP Delivery:
  • pHLIP-conjugated peptides (pHLIP-P4 and pHLIP-phosphoP4) successfully inserted into membranes and activated PTP1B only at acidic pH (pH 6).
  • At neutral pH (pH 8), no activation or EGFR dephosphorylation was observed, confirming the pH-dependent targeting capability.

5. Significance

• Therapeutic Paradigm Shift: This work challenges the prevailing drug discovery focus on kinase inhibitors by demonstrating that activating phosphatases via PPI disruption is a viable therapeutic strategy for cancers driven by hyperactive RTK signaling.
• Redox Regulation: It provides a concrete mechanism for how the redox cycle of PTPs can be manipulated therapeutically. By preventing the "stabilization" of the oxidized state, the natural reactivation of the enzyme is preserved.
• Clinical Potential: The use of pHLIP addresses the major hurdle of peptide drug delivery (poor membrane permeability and lack of specificity). This approach allows for the selective activation of PTP1B within the acidic tumor microenvironment, potentially reducing systemic toxicity.
• Broad Applicability: The authors propose that this strategy could be extended to other members of the PTP superfamily, offering a foundation for correcting dysregulated signaling pathways in various diseases beyond cancer.